Table 4.

Correlation of SMAD gene expression level with overall survival (OS) of gastric cancer patients under different treatment strategies

SMADs	Treatments	Cases	HR (95% CI)	P-value
SMAD1	Surgery alone	380	0.69 (0.49 − 0.97)	0.03*
	5-FU-based adjuvant	34	0.52 (0.21 − 1.31)	0.16
	Other adjuvant	76	0.5 (0.2 − 1.25)	0.13
SMAD2	Surgery alone	380	0.65 (0.48 − 0.89)	0.0068*
	5-FU-based adjuvant	153	1.31 (0.89 − 1.93)	0.16
	Other adjuvant	76	0.56 (0.23 − 1.38)	0.2
SMAD3	Surgery alone	380	1.41 (1 − 1.99)	0.051
	5-FU-based adjuvant	153	2.23 (1.46 − 3.42)	0.00015*
	Other adjuvant	76	1.85 (0.67 − 5.1)	0.23
SMAD4	Surgery alone	380	0.75 (0.56 − 1)	0.046*
	5-FU-based adjuvant	153	0.72 (0.49 − 1.04)	0.077
	Other adjuvant	76	0.45 (0.13 − 1.52)	0.18
SMAD5	Surgery alone	380	1.36 (0.97 − 1.91)	0.07
	5-FU-based adjuvant	153	0.38 (0.25 − 0.57)	1.3e−06*
	Other adjuvant	76	0.4 (0.15 − 1.11)	0.069
SMAD6	Surgery alone	380	1.17 (0.88 − 1.56)	0.28
	5-FU-based adjuvant	153	1.77 (1.23 − 2.55)	0.002*
	Other adjuvant	76	1.56 (0.65 − 3.78)	0.32
SMAD7	Surgery alone	380	1.64 (1.21 − 2.22)	0.0012*
	5-FU-based adjuvant	153	1.16 (0.82 − 1.63)	0.4
	Other adjuvant	76	1.8 (0.74 − 4.34)	0.19
SMAD9	Surgery alone	380	1.58 (1.17 − 2.14)	0.0029*
	5-FU-based adjuvant	34	1.67 (0.67 − 4.17)	0.27
	Other adjuvant	76	2.86 (1.14 − 7.19)	0.019*

*P < 0.05

Abbreviations: 5-FU, 5-Fluorouracil; CI, confidence interval; HR, hazard ratio.